LAVA Therapeutics NV isa clinical stage immuno-oncology company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LVTX is expected to report earnings to fall 11.11% to -23 cents per share on March 19
Q4'25
Est.
$-0.24
Q3'25
Missed
by $0.03
Q2'25
Missed
by $0.02
Q1'25
Beat
by $0.19
Q4'24
Beat
by $0.16
The last earnings report on November 12 showed earnings per share of -27 cents, missing the estimate of -24 cents. With 187.24K shares outstanding, the current market capitalization sits at 42.09M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. LVTX showed earnings on November 12, 2025. You can read more about the earnings report here.